Yahoo Italia Ricerca nel Web

Entra

Risultati di ricerca

  1. www.marketscreener.com › quote › stockRatings Ipsen - MarketScreener.com

    30 ago 2024 · Highlights: Ipsen. The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes. Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.

  2. Immagini

    • Bodil Ipsen – Movies, Bio and Lists on MUBI
    • Bodil Ipsen | Det Danske Filminstitut
    • Bodil Ipsen - Dansk skuespiller - Biografi - lex.dk
    • arkiv.dk | Bodil Ipsen
    • Bodil Ipsen, 1916, as Ophelia, Kroneburg Castle, Denmark; 100 years ago ...
    • Dansk Film & Teater - Bodil Ipsen
    • Bodil Ipsen Facts for Kids

    Mostra tutto

  3. www.forbes.com › profile › henri-beaufourHenri Beaufour - Forbes

    5 giorni fa · Henri Beaufour owes his fortune to his stake in Ipsen, a French pharmaceutical giant that sells more than 25 drugs in 115 countries.

  4. www.bloomberg.com › quote › IPN:FPIPN: Ipsen SA Stock Price Quote - EN Paris - Bloomberg

    4 giorni fa · Stock analysis for Ipsen SA (IPN:EN Paris) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

    • 5K

  5. pharmaphorum.com › news › ipsen-licenses-sutro-adc-900m-dealIpsen licenses Sutro ADC in $900m deal - pharmaphorum

    4 giorni fa · Ipsen has expanded its oncology pipeline by licensing rights to an antibody-drug conjugate (ADC) for solid tumours from Sutro Biopharma, its first drug in the category.

  6. markets.ft.com › data › equitiesIpsen SA, IPN:PAR profile - FT.com - Financial Times

    6 giorni fa · Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In...

  7. Video

    Mostra tutto

  8. pharmaphorum.com › news › fda-clears-ipsens-primary-biliaryFDA clears Ipsen’s primary biliary cholangitis drug

    3 giorni fa · Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

  9. markets.ft.com › data › equitiesIpsen SA, IPN:PAR summary - FT.com - Financial Times

    4 giorni fa · Key statistics. On Friday, Ipsen SA (IPN:PAR) closed at 108.00, 8.32% above its 52-week low of 99.70, set on Mar 01, 2024. 52-week range. Today. 99.70 Mar 01 2024 130.70 Sep 15 2023.